The 5 most recent market catalysts affecting $CRDF, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bearish
Impact 85
Cardiff Oncology Announces Settlement With Nerviano Medical Sciences And Amended 2017 Onvansertib License Agreement, Resolving All Litigation; Parties To Seek Dismissal With Prejudice
The resolution of litigation with Nerviano Medical Sciences is a significant positive for Cardiff Oncology (CRDF). Legal disputes can be a major drain on resources and create uncer…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate
Cardiff Oncology (CRDF) announced its Q2 financial results, reporting a smaller loss per share than anticipated by analysts and sales that surpassed consensus estimates. This posit…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 85
Cardiff Oncology shares are trading lower after the company announced a $10 million offering of 8,571,429 shares of its common stock and accompanying warrants at $1.05 per share and accompanying warrant.
The headline indicates a significant dilutive event for Cardiff Oncology. Issuing new shares and warrants at a price below the current market value (implied by the stock trading lo…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 75
Cardiff Oncology Announces $10M Registered Direct Offering Of 8,571,429 Shares An Accompanying Warrants At $1.05 Per Share And Accompanying Warrant
This registered direct offering by Cardiff Oncology is a significant corporate catalyst. The issuance of new shares and warrants at $1.05 per share, below its recent trading price,…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.